Damaged myocytes as detected by the colocalization of DNA fragmentation and tissue transglutaminase and their prognostic significance in enterovirus-associated dilated cardiomyopathy
Hospital Waltershausen-Friedrichroda, Friedrichroda, Germany, Friedrich-Schiller-University, Jena, Germany. European Journal of Clinical Investigation
(Impact Factor: 2.73).
10/2001; 31(9):744-55. DOI: 10.1046/j.1365-2362.2001.00878.x
Apoptotic cardiac myocytes have been described in chronic heart failure, but no data exist on the relationship between these 'damaged' myocytes and myocardial detection of enterovirus RNA often associated with dilated cardiomyopathy (DCM).
In patients with idiopathic DCM, endomyocardial biopsy samples were studied for enteroviral RNA by one step reverse transcription-polymerase chain reaction (PCR) and a subsequent hybridization of the PCR product using a Southern blot technique. The endomyocardial biopsies were further investigated for markers of cell damage and apoptosis: DNA fragmentation and expression of tissue-transglutaminase (TTG) in the myocytes using the in-situ endlabelling method or an anti-TTG-staining, respectively. To assess the prognostic significance of these two markers the correlation between the percentage of myocytes positive both for DNA fragmentation and TTG (the index of damaged myocytes) and the hemodynamic course of the patients during a mean follow-up period of 15.9 +/- 6.2 months was investigated prospectively by echocardiography.
In 14 (45%) of the 31 patients with idiopathic DCM, enteroviral RNA was found in the endomyocardial biopsy samples, while 17 patients (55%) were enterovirus-negative. In enterovirus-positive patients, the index of 'damaged' myocytes was significantly lower (10.7 +/- 4.9% vs. 19.2 +/- 8.8%, P = 0.002) and the left ventricular ejection fraction (LVEF) improved significantly (P = 0.00017 vs. P = 0.13) during long-term follow-up. In addition, a weak negative correlation was seen between the index of damaged myocytes and the changes in LVEF in all patients during long-term follow-up (r = - 0.48, P = 0.004).
Our results favour the view that enterovirus-positive patients with DCM have less damaged myocytes and a better haemodynamic course than enterovirus-negative patients.
Available from: db-thueringen.de
- "r . med . A . Stelzner ) mittels der Guanidin - Thiocyanat - Phenol - Chlorophorm - Methode nach Chromczynski und Sacchi ( 1987 ) durchgeführt . Dafür wurde das gewonnene Gewebe gleichmäßig in einer 4M Guanidin - Thiocynat - Mercaptophenollösung homogenisiert . Die RNA wurde mit Hilfe von Phenol - Chlorophorm ausgefällt und mit Ethanol gewaschen ( Lotze et al . , 2001"
[Show abstract] [Hide abstract]
ABSTRACT: Über die prognostische Bedeutung des Nachweises von myokardialer Enterovirus-RNA bei der idiopathischen DCM lagen zu Studienbeginn 1998 nur zwei Langzeituntersuchungen mit konträren Ergebnissen hinsichtlich der Mortalität der Patienten vor. Ziel dieser prospektiven Studie war es daher bei Patienten mit idiopathischer DCM die prognostische Bedeutung des Nachweises von Enterovirus-RNA im Myokard hinsichtlich des klinischen und hämodynamischen Verlaufes dieser chronischen Herzmuskelerkrankung über einen Mindestbeobachtungszeitraum von 12 Monaten zu untersuchen. In der vorliegenden Studie wurden 64 Patienten (55 Männer, Alter 51+11 Jahre) untersucht, bei denen nach klinischer und invasiver Diagnostik mittels Myokardbiopsie (histologischen und immunhistologischen Beurteilung der Myokardbiopsien; Nachweis enteroviraler RNA mit Hilfe der RT-PCR und anschließender Southern-Blot-Hybridisierung) die Diagnose einer DCM gestellt werden konnte. Bei 26/64 (41%) Patienten konnte Enterovirus-RNA im Myokard nachgewiesen werden, 38/64 (59%) Patienten waren Enterovirus-negativ. Aus den vorliegenden Ergebnissen lässt sich die Schlussfolgerung ziehen, dass es sich bei der Enterovirus-assozierten DCM um eine Untergruppe der DCM mit günstiger Prognose handelt, woraus abgeleitet werden kann, dass der Nachweis von enteroviraler RNA im Myokard von prädiktivem Wert für den Krankheitsverlauf der idiopathischen DCM zu sein scheint.
[Show abstract] [Hide abstract]
ABSTRACT: For celiac disease (CD), screening a trend has recently emerged to measure tissue transglutaminase antibodies (tTGA) by immunoassays instead of the more laborious endomysial antibodies (EmA), as they recognize the same target, tissue transglutaminase (tTG). However, a high rate of false-positive results has been reported in some patient series with diseases known to be associated with CD. Moreover, tTG is a ubiquitous, multifunctional enzyme, overexpressed in experimental models of heart failure. Therefore, we assessed the specificity of tTGA assays in a large series of EmA-negative patients with end-stage heart failure.
We studied 288 patients with end-stage heart failure and 60 blood donors. No subject had clinical evidence of CD or IgA deficiency, and all were EmA negative. Serum IgA and IgG tTGA were measured by means of commercial kits using as substrate, either guinea pig or recombinant human tTG. Blocking studies and Western blots were also performed using recombinant human tTG.
All blood donor sera were IgA tTGA negative. IgA tTGA positivity was observed in 47.6% and 49.1% of patients with heart failure using, respectively, guinea pig tTG and recombinant human tTG as substrates. Preincubation of positive sera with recombinant human tTG resulted in 81% blocking of IgA tTGA in immunoassay. Western blot analysis confirmed the presence of antibodies against recombinant human tTG. IgA tTGA-positive sera were also IgG tTGA positive.
IgA and IgG tTGA occur in a large number of EmA-negative patients with end-stage heart failure, and their presence is unlikely to be caused by concomitant CD.
The American Journal of Gastroenterology 12/2002; 97(11):2850-4. DOI:10.1111/j.1572-0241.2002.07033.x · 10.76 Impact Factor
[Show abstract] [Hide abstract]
ABSTRACT: The association of enteroviruses with myocardial disease has been investigated extensively by molecular biological techniques to detect viral RNA, but remains controversial. This retrospective study investigated the involvement of enterovirus in myocarditis or dilated cardiomyopathy (DCM) by detection of viral antigens in myocardial samples from a new patient series using an optimized immunohistochemical technique. Formalin-fixed, paraffin-embedded biopsy, autopsy or explanted myocardial tissue samples were obtained from 136 subjects. These comprised histologically proven cases of acute fatal myocarditis (n=10), DCM (n=89, including 10 patients with healing/borderline myocarditis) and a comparison group of samples from 37 unused donor hearts and cases with other conditions. A monoclonal antibody 5-D8/1 directed against a conserved, non-conformational epitope in capsid protein VP1 was employed for broad detection of different enterovirus serotypes. Investigations were performed blindly. Histological sections from 7 of 10 fatal myocarditis cases, 47 of 89 patients (52.8%) with DCM were positive for the viral capsid protein VP1 by immunohistochemical staining. Consecutive sections of positive samples were negative when the antibody was omitted or replaced with subclass- and concentration-matched normal mouse IgG. In contrast, only 3 of 37 samples (8.1%) in the comparison group were positive (Yates corrected chi(2)=19.99, P<0.001: odds ratio =12.68). VP1 staining was distributed in individual or grouped myofibers and localized in the cytoplasm of myocytes. In some cases, VP1 was detected in only a few myofibers within an entire section. These results provide further evidence of enterovirus involvement in a high proportion of DCM cases and demonstrate that VP1 is present in disease stages from acute myocarditis, healing myocarditis to end-stage DCM requiring cardiac transplantation, indicating translation of viral protein during persistent enterovirus infection.
Medical Microbiology and Immunology 05/2004; 193(2-3):109-14. DOI:10.1007/s00430-003-0208-8 · 3.04 Impact Factor
Data provided are for informational purposes only. Although carefully collected, accuracy cannot be guaranteed. The impact factor represents a rough estimation of the journal's impact factor and does not reflect the actual current impact factor. Publisher conditions are provided by RoMEO. Differing provisions from the publisher's actual policy or licence agreement may be applicable.